CLOs on the Move

Motus GI

www.motusgi.com

 
Motus GI Holdings, Inc. (NASDAQ: MOTS) is a medical technology company based in the U.S., with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.motusgi.com
  • 1301 E. Broward Blvd. Suite 310
    Fort Lauderdale, FL USA 33301
  • Phone: 954.541.8000

Executives

Name Title Contact Details

Similar Companies

NuVera Medical

NuVera Medical, Inc., a portfolio company of Shifamed, LLC., is a privately held company focused on the development of a novel imaging platform for use in a growing number of complex cardiovascular procedures.

Remcore

Remcore is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Codan US Corporation

Codan US Corporation is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cordis

With more than a 60-year history of pioneering products to treat millions of patients, Cordis is a worldwide leader in the development and manufacturing of interventional cardiovascular technology. Cordis established a legacy of high-quality and minimally-invasive cardiovascular products; and has built a robust global footprint with operations in more than 60 countries around the world. As from August 2, 2021, Cordis is a standalone company, and is committed to investing $300 million to accelerate innovation in its broad product portfolio. Building on our storied brand, we are unleashing our potential to be a $10 billion leader bringing new technology to the market through bold action at speed.

EnteroMedics

EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals. vBloc Therapy is now approved by the Food and Drug Administration for weight loss in adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels.* *Individuals should have first tried to lose weight by diet and exercise in a supervised program within the last 5 years before receiving the Maestro System.